RAPT Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by HC Wainwright

HC Wainwright upgraded shares of RAPT Therapeutics (NASDAQ:RAPT) from a neutral rating to a buy rating in a report released on Thursday morning, MarketBeat.com reports. HC Wainwright currently has $10.00 target price on the stock.

Several other brokerages also recently commented on RAPT. UBS Group cut their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a report on Monday, September 9th. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $8.00 to $2.00 in a report on Monday, November 11th. Wells Fargo & Company cut their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.56.

RAPT Therapeutics Price Performance

RAPT opened at $1.81 on Thursday. RAPT Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $27.35. The firm has a market capitalization of $63.27 million, a P/E ratio of -0.65 and a beta of 0.07. The company’s 50-day moving average is $1.50 and its 200 day moving average is $2.19.

RAPT Therapeutics (NASDAQ:RAPT) last released its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. On average, equities research analysts expect that RAPT Therapeutics will post -2.86 earnings per share for the current year.

Institutional Trading of RAPT Therapeutics

A number of institutional investors have recently made changes to their positions in RAPT. Federated Hermes Inc. grew its holdings in shares of RAPT Therapeutics by 188.7% during the second quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock valued at $2,428,000 after buying an additional 520,368 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of RAPT Therapeutics by 176,725.0% in the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock valued at $2,157,000 after purchasing an additional 706,900 shares during the period. Acadian Asset Management LLC raised its stake in shares of RAPT Therapeutics by 4,183.3% in the second quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock worth $1,424,000 after purchasing an additional 456,275 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of RAPT Therapeutics by 826.4% during the second quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock worth $900,000 after purchasing an additional 263,372 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of RAPT Therapeutics by 108.1% in the second quarter. Renaissance Technologies LLC now owns 203,900 shares of the company’s stock worth $622,000 after acquiring an additional 105,900 shares during the period. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.